BRPI0910559A2 - associação da dronedarona com pelo menos um diurético, e sua aplicação em terapêutica. - Google Patents
associação da dronedarona com pelo menos um diurético, e sua aplicação em terapêutica.Info
- Publication number
- BRPI0910559A2 BRPI0910559A2 BRPI0910559A BRPI0910559A BRPI0910559A2 BR PI0910559 A2 BRPI0910559 A2 BR PI0910559A2 BR PI0910559 A BRPI0910559 A BR PI0910559A BR PI0910559 A BRPI0910559 A BR PI0910559A BR PI0910559 A2 BRPI0910559 A2 BR PI0910559A2
- Authority
- BR
- Brazil
- Prior art keywords
- dronedarone
- diuretic
- therapy
- association
- application
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0802128A FR2930149B1 (fr) | 2008-04-17 | 2008-04-17 | Association de dronedarone avec au moins un diuretique, son application en therapeutique |
US4599908P | 2008-04-18 | 2008-04-18 | |
PCT/FR2009/000450 WO2009133310A2 (fr) | 2008-04-17 | 2009-04-16 | Association de la dronedarone avec au moins un diuretique, son application en therapeutique |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0910559A2 true BRPI0910559A2 (pt) | 2015-09-22 |
Family
ID=39684441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0910559A BRPI0910559A2 (pt) | 2008-04-17 | 2009-04-16 | associação da dronedarona com pelo menos um diurético, e sua aplicação em terapêutica. |
Country Status (26)
Country | Link |
---|---|
US (1) | US20110136899A1 (pt) |
EP (1) | EP2280700A2 (pt) |
JP (1) | JP2011517694A (pt) |
KR (1) | KR20110005245A (pt) |
CN (1) | CN102065856A (pt) |
AR (1) | AR071326A1 (pt) |
AU (1) | AU2009241966A1 (pt) |
BR (1) | BRPI0910559A2 (pt) |
CA (1) | CA2721560A1 (pt) |
CL (1) | CL2009000918A1 (pt) |
CO (1) | CO6300842A2 (pt) |
CR (1) | CR11735A (pt) |
DO (1) | DOP2010000308A (pt) |
EA (1) | EA201071203A1 (pt) |
EC (1) | ECSP10010552A (pt) |
FR (1) | FR2930149B1 (pt) |
IL (1) | IL208749A0 (pt) |
MA (1) | MA32355B1 (pt) |
MX (1) | MX2010011401A (pt) |
NI (1) | NI201000171A (pt) |
PE (1) | PE20091808A1 (pt) |
SV (1) | SV2010003702A (pt) |
TW (1) | TW200951117A (pt) |
UY (1) | UY31772A (pt) |
WO (1) | WO2009133310A2 (pt) |
ZA (1) | ZA201007390B (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR072950A1 (es) | 2008-04-17 | 2010-10-06 | Sanofi Aventis | Uso de dronedarona para la preparacion de un medicamento para uso en la prevencion de la hospitalizacion cardiovascular o de la mortalidad, composicion farmaceutica, articulo de fabricacion y envase |
FR2930150B1 (fr) * | 2008-06-24 | 2011-01-14 | Sanofi Aventis | Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang |
EP2116239A1 (en) * | 2008-04-29 | 2009-11-11 | Sanofi-Aventis | Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment |
US8602215B2 (en) | 2010-06-30 | 2013-12-10 | Sanofi | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4868179A (en) * | 1987-04-22 | 1989-09-19 | Cohn Jay N | Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate |
US4988513A (en) * | 1990-01-09 | 1991-01-29 | Monsanto Company | Method of treating hypokalemia |
FR2665444B1 (fr) * | 1990-08-06 | 1992-11-27 | Sanofi Sa | Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant. |
FR2735365B1 (fr) * | 1995-06-14 | 1997-09-05 | Sanofi Sa | Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires |
FR2746013B1 (fr) * | 1996-03-18 | 1998-05-29 | Sanofi Sa | Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus |
US6083991A (en) * | 1997-06-04 | 2000-07-04 | University Of Florida Research Foundation, Inc. | Anti-arrhythmic composition and methods of treatment |
FR2764800B1 (fr) * | 1997-06-23 | 1999-09-10 | Sanofi Sa | Composition pharmaceutique solide contenant des derives de benzofuranne |
US6897305B2 (en) * | 1998-06-08 | 2005-05-24 | Theravance, Inc. | Calcium channel drugs and uses |
US20030113330A1 (en) * | 1999-11-08 | 2003-06-19 | Uhal Bruce D. | Methods for treating pulmonary fibrosis |
US6411840B1 (en) * | 1999-11-16 | 2002-06-25 | Cardiac Intelligence Corporation | Automated collection and analysis patient care system and method for diagnosing and monitoring the outcomes of atrial fibrillation |
FR2803846B1 (fr) * | 2000-01-17 | 2002-04-05 | Clariant France Sa | 3-(1-hydroxy-pentylidene)-5-nitro-3h-benzofuran-2-one, son procede de preparation et son utilisation |
FR2817864B1 (fr) * | 2000-12-11 | 2003-02-21 | Sanofi Synthelabo | Derive de methanesulfonamido-benzofurane, son procede de preparation et son utilisation comme intermediaire de synthese |
FR2817865B1 (fr) * | 2000-12-11 | 2005-02-18 | Sanofi Synthelabo | Derive aminoalkoxybenzoyle sous forme de sel, son procede de preparation et son utilisation comme intermediaire de synthese |
FR2817750B1 (fr) * | 2000-12-11 | 2003-02-21 | Sanofi Synthelabo | Composition pharmaceutique de dronedarone pour administration parenterale |
DE60117857D1 (de) * | 2000-12-27 | 2006-05-04 | Genzyme Corp | Kontrollierte freisetzung von anti-arrhythmica aus einem biodegradierbaren hydrogel für die lokale anwendung am herzen |
US6831102B2 (en) * | 2001-12-07 | 2004-12-14 | Bristol-Myers Squibb Company | Phenyl naphthol ligands for thyroid hormone receptor |
US20030229007A1 (en) * | 2002-05-30 | 2003-12-11 | Roberto Levi | Form of human renin and its use as a target in treatments for cardiac ischemia and arrhythmia |
DE10237819A1 (de) * | 2002-08-19 | 2004-03-04 | Bayer Ag | 5-Nitrobenzofurane |
US20050004194A1 (en) * | 2003-05-15 | 2005-01-06 | Graves Kurt Chum | Use of organic compounds |
US20060093673A1 (en) * | 2003-06-27 | 2006-05-04 | Coury Arthur J | Controlled release of anti-arrhythmic agents |
WO2005018635A2 (en) * | 2003-08-07 | 2005-03-03 | Cardiome Pharma Corp. | Ion channel modulating activity i |
US7820702B2 (en) * | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
US20050182105A1 (en) * | 2004-02-04 | 2005-08-18 | Nirschl Alexandra A. | Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function |
US7772232B2 (en) * | 2004-04-15 | 2010-08-10 | Bristol-Myers Squibb Company | Quinazolinyl compounds as inhibitors of potassium channel function |
FR2875409B1 (fr) * | 2004-09-17 | 2010-05-07 | Sanofi Aventis | Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose |
US20070248564A1 (en) * | 2006-04-25 | 2007-10-25 | Roxane Laboratories, Inc. | Formulation of sodium polystyrene sulfonate suspension for the treatment of hyperkalemia |
US20090076137A1 (en) * | 2007-09-19 | 2009-03-19 | Protia, Llc | Deuterium-enriched dronedarone |
AR072950A1 (es) * | 2008-04-17 | 2010-10-06 | Sanofi Aventis | Uso de dronedarona para la preparacion de un medicamento para uso en la prevencion de la hospitalizacion cardiovascular o de la mortalidad, composicion farmaceutica, articulo de fabricacion y envase |
FR2930150B1 (fr) * | 2008-06-24 | 2011-01-14 | Sanofi Aventis | Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang |
EP2116239A1 (en) * | 2008-04-29 | 2009-11-11 | Sanofi-Aventis | Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment |
EP2133075A1 (en) * | 2008-06-10 | 2009-12-16 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament intended for the prevention of cardioversion |
EP2133074A1 (en) * | 2008-06-10 | 2009-12-16 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation |
EP2153830A1 (en) * | 2008-08-07 | 2010-02-17 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament intended for the prevention of stroke or transient ischemic attack |
FR2959132A1 (fr) * | 2010-04-22 | 2011-10-28 | Sanofi Aventis | Procedes pour l'evaluation et la reduction des risques |
US20120005128A1 (en) * | 2010-06-29 | 2012-01-05 | Sanofi | Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation |
US8602215B2 (en) * | 2010-06-30 | 2013-12-10 | Sanofi | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
-
2008
- 2008-04-17 FR FR0802128A patent/FR2930149B1/fr not_active Expired - Fee Related
-
2009
- 2009-04-15 PE PE2009000519A patent/PE20091808A1/es not_active Application Discontinuation
- 2009-04-15 AR ARP090101316A patent/AR071326A1/es unknown
- 2009-04-16 AU AU2009241966A patent/AU2009241966A1/en not_active Abandoned
- 2009-04-16 KR KR1020107023064A patent/KR20110005245A/ko not_active Application Discontinuation
- 2009-04-16 CL CL2009000918A patent/CL2009000918A1/es unknown
- 2009-04-16 CN CN2009801229250A patent/CN102065856A/zh active Pending
- 2009-04-16 WO PCT/FR2009/000450 patent/WO2009133310A2/fr active Application Filing
- 2009-04-16 JP JP2011504499A patent/JP2011517694A/ja active Pending
- 2009-04-16 BR BRPI0910559A patent/BRPI0910559A2/pt not_active IP Right Cessation
- 2009-04-16 EP EP09738344A patent/EP2280700A2/fr not_active Withdrawn
- 2009-04-16 MX MX2010011401A patent/MX2010011401A/es not_active Application Discontinuation
- 2009-04-16 CA CA2721560A patent/CA2721560A1/fr not_active Abandoned
- 2009-04-16 EA EA201071203A patent/EA201071203A1/ru unknown
- 2009-04-17 TW TW098112872A patent/TW200951117A/zh unknown
- 2009-04-17 UY UY0001031772A patent/UY31772A/es not_active Application Discontinuation
-
2010
- 2010-10-13 US US12/903,374 patent/US20110136899A1/en not_active Abandoned
- 2010-10-14 CR CR11735A patent/CR11735A/es not_active Application Discontinuation
- 2010-10-14 IL IL208749A patent/IL208749A0/en unknown
- 2010-10-14 SV SV2010003702A patent/SV2010003702A/es unknown
- 2010-10-14 NI NI201000171A patent/NI201000171A/es unknown
- 2010-10-15 DO DO2010000308A patent/DOP2010000308A/es unknown
- 2010-10-15 CO CO10128306A patent/CO6300842A2/es not_active Application Discontinuation
- 2010-10-15 ZA ZA2010/07390A patent/ZA201007390B/en unknown
- 2010-10-15 EC EC2010010552A patent/ECSP10010552A/es unknown
- 2010-11-03 MA MA33318A patent/MA32355B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
CO6300842A2 (es) | 2011-07-21 |
WO2009133310A2 (fr) | 2009-11-05 |
ZA201007390B (en) | 2012-01-25 |
PE20091808A1 (es) | 2009-12-03 |
CR11735A (es) | 2010-11-22 |
MA32355B1 (fr) | 2011-06-01 |
JP2011517694A (ja) | 2011-06-16 |
IL208749A0 (en) | 2010-12-30 |
NI201000171A (es) | 2012-01-23 |
US20110136899A1 (en) | 2011-06-09 |
WO2009133310A3 (fr) | 2009-12-23 |
AU2009241966A1 (en) | 2009-11-05 |
CN102065856A (zh) | 2011-05-18 |
MX2010011401A (es) | 2011-03-02 |
CL2009000918A1 (es) | 2010-06-11 |
ECSP10010552A (es) | 2010-11-30 |
FR2930149B1 (fr) | 2011-02-18 |
FR2930149A1 (fr) | 2009-10-23 |
EA201071203A1 (ru) | 2011-06-30 |
TW200951117A (en) | 2009-12-16 |
KR20110005245A (ko) | 2011-01-17 |
CA2721560A1 (fr) | 2009-11-05 |
EP2280700A2 (fr) | 2011-02-09 |
SV2010003702A (es) | 2011-03-04 |
UY31772A (es) | 2009-12-14 |
AR071326A1 (es) | 2010-06-09 |
DOP2010000308A (es) | 2010-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LTPA2017019I1 (lt) | Žmogaus antikūnai, pasižymintys dideliu giminingumu PCSK9 | |
BRPI0906549A2 (pt) | Bandagens médicas com válvulas e kits contendo as mesmas. | |
BR112012003792A2 (pt) | gel tópico, e, uso do gel tópico. | |
BRPI0911351A2 (pt) | estrutura de sent, e , prótese de válvula. | |
BRPI1010957A2 (pt) | variantes de celulase com expressão, atividade e/ou estabilidade aprimorada e uso das mesmas. | |
CL2007001911A1 (es) | Uso de un componente neurotoxico de un complejo de toxina de clostridium botulinum, en donde la composicion carece de cualquier otro componente proteico del complejo para tratar una afeccion asociada con la inervacion colinergica muscular hiperactiva | |
BRPI1005322A2 (pt) | anticorpo, composição farmacêutica e uso de pelo menos um anticorpo | |
BRPI1015547A2 (pt) | aparelho utilizável com um poço, válvula de retenção utilizável em um poço, e disposição de válvula de retenção útil em um poço. | |
BRPI0812310A2 (pt) | Componente de mancal, mancal de rolamento e mancal de deslizamento | |
BRPI0906936A2 (pt) | Uso de canabinóide canabidiol e canabinóide tetraidrocanabivarina | |
FR2884516B1 (fr) | Antagonistes npy, preparation et utilisations | |
BRPI0816097A2 (pt) | composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição. | |
BRPI0718192A2 (pt) | Corantes dispersos, sua preparação e seu uso. | |
BRPI0719250A2 (pt) | Métodos e composições com opalescência reduzida. | |
BRPI0919412A8 (pt) | composição imunonutricional e nutricional,agente intensificador de resposta imunológica e uso do mesmo. | |
BRPI0719345A2 (pt) | Di-hidroimidazóis substituídos e seu uso no tratamento de tumores. | |
NL1036050C (nl) | Brandvertragende en brandwerende samenstelling. | |
BRPI0814931A2 (pt) | Composto com atividade contra hcv, sua composição e seu uso | |
BRPI0917728A2 (pt) | composição, uso da composição, e, método de prevenção da formação de espuma em uma composição | |
BRPI0817974A2 (pt) | Combinações de substâncias ativas com propriedades inseticidas e acaricidas. | |
BRPI0909828A2 (pt) | corantes dispersos de azopiridona, sua preparação e uso | |
BRPI0911772A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
BRPI0910559A2 (pt) | associação da dronedarona com pelo menos um diurético, e sua aplicação em terapêutica. | |
BRPI0922908A2 (pt) | "composição compreendendo pelo menos dois cicloalquilmeticonas diferentes e uso deste". | |
FR2908766B1 (fr) | Derives de pyrrole,leur preparation et leur utilisation en therapeutique. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |